The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:
A person shall be entitled to a patent unless –
(a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention.
Claims 1-4 and 7 are rejected under 35 U.S.C. 102(a)(1) as being clearly anticipated by Wang (CN 109972991). On page 2 of the patent publication Wang teaches the following 2 compounds.
PNG
media_image1.png
200
400
media_image1.png
Greyscale
These two compounds are anticipatory of the structure found in claims 1-2. The first structure is also anticipatory of claims 3-4 and 7.
Claims 1-4 and 7 are rejected under 35 U.S.C. 102(a)(1) as being clearly anticipated by Liu (Dyes and Pigments 2007). Figure 2of Liu shows the synthesis of sone dyes. In the synthesis Compound 7,
PNG
media_image2.png
200
400
media_image2.png
Greyscale
, in which n = 3 and 8 is anticipatory of the structures found in claims 1-2. When n = 3, the structure is also anticipatory of claims 3-4 and 7.
Claims 1 and 6-7 are rejected under 35 U.S.C. 102(a)(1) as being clearly anticipated by Jefferies (US 3,839,426). With respect to claim 1, Column 24, line 44 to column 26, line 31 teach the synthesis of 4 different quaternary ammonium chlorides. Column 26, lines 23-31 teach that in addition to those for which detailed preparations are given, the following quaternary ammonium intermediates are obtained when the indicated nitrophenyl-substituted quaternizing agent is interacted with the indicated tertiary amino compound. Of relevance to the instant claims is column 26, lines 69-71 teaching N-Methyl-N-isobutyl-N-3-hydroxybutyl-N-4-aminobenxylarmmonium iodide starting with N-3-hydroxybutyl- N-isobutylmethylamine and 4-nitrobenzyl iodide. The N-Methyl-N-isobutyl-N-3-hydroxybutyl-N-4-aminobenxylarmmonium iodide is anticipatory of claims 1 and 6-7.
The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action:
A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made.
The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows:
1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.
This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention.
Claim(s) 5, 7 and 10 are rejected under 35 U.S.C. 103 as being unpatentable over Wang or Liu as applied to claims 1-2 above, and further in view of Soleimani-Gorgani. The compounds of Wan and Liu are used in the synthesis of cationic dyes containing at least one azo group. Wang and Liu do not teach that the R groups are the same and are a methyl group or an ethyl group.
In the paper Soleimani-Gorgani teaches cationic reactive dyes for nylon. Table 1 on page 611 shows the dye structures. Schemes 1 and 2 on page 612 show different methods of synthesizing a m-aminophenyltrimethylammonium salt. Scheme 3 in the same page shows the use of the m-aminophenyltrimethylammonium salt to form one of the dyes.
With respect to claim 5, it would have been obvious to one of ordinary skill in the art at the time the application was filed to substitute the trimethylammonium salt structure Soleimani-Gorgani for the propyldimethyl ammonium salt structures used by Wang or Liu because the salt structure of Soleimani-Gorgani is similar to the salt structure of Wang and Liu and is being used for the same purpose in the dyes of Liu, Soleimani-Gorgani and Wang providing an expectation that the substitution would perform the same function when incorporated into the Liu and Wang dyes. With respect to claim 7, its scope includes the structure of claim 5 so that the obviousness of claim 5 extends to claim 7. With respect to claim 10, the proposed substitution into the Wang compound would produce compound CB467b so that claim 10 is obvious for the reasons given above for claim 5. Additionally with respect to claim 10the proposed substitution into the Liu compound would produce compound CB466x so that claim 10 is also obvious for the reasons given above for claim 5.
Claims 11-20 are allowed.
Claims 8-9 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.
The following is a statement of reasons for the indication of allowable subject matter: the art of record fails to teach or fairly suggest the required structure of the compounds of claims 8-9 or the mixed mode chromatography medium of claim 11.
The prior art made of record and not relied upon is considered pertinent to applicant's disclosure. The additionally cited art relates to structure similar to the above applied references.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to Arlen Soderquist whose telephone number is (571)272-1265. The examiner can normally be reached 1st week Monday-Thursday, 2nd week Monday-Friday.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Lyle Alexander can be reached at (571)272-1254. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/ARLEN SODERQUIST/ Primary Examiner, Art Unit 1797